Veterinary Medicines

Bovilis IBR marker Live

Authorised
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Download as PDF

Product identification

Medicine name:
BOVILIS IBR MARKER LIVE ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Bovilis IBR marker Live
Active substance:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
Target species:
  • Cattle
Route of administration:
  • Nasal use
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated
    5.70
    log10 50% tissue culture infectious dose
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Nasal use
    • Cattle
      • Milk
        no withdrawal period
      • Meat and offal
        no withdrawal period
  • Intramuscular use
    • Cattle
      • Milk
        no withdrawal period
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (100 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (10 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (20 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 PET vials of solvent (100 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (5 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (25 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 glass vial (hydrolytic type II) of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 PET vial of solvent (100 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (5 doses) and 1 glass vial (hydrolytic type II) of solvent (10 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (25 doses) and 1 glass vial (hydrolytic type II) of solvent (50 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (100 doses) and 1 glass vial (hydrolytic type II) of solvent (200 ml)
  • Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (10 doses) and 1 glass vial (hydrolytic type II) of solvent (20 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 62247/09-10-2006/K-0142503
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0105/001
Concerned member states:
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)